VEGFC and neoplasm: The authors suggest that VEGF-C enhances immunotherapy by attracting naïve T cells being locally activated upon immunotherapy induced tumor cell killing, and that serum VEGF-C may serve as a predictive biomarker for immunotherapy response [62].